Clinical Trial Update: Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

View source ↗

Summary

An expanded-access program offers intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NP) for progressive multiple sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MSC-NP (autologous mesenchymal stem cell-derived neural progenitors)

Snippet

Sponsor: Tisch Multiple Sclerosis Research Center of New York | Conditions: Multiple Sclerosis | Status: AVAILABLE